FGTI-2734 mesylate |
| Catalog No.GC39276 |
Le mésylate de FGTI-2734 est un mimétique RAS C-terminal double farnésyl transférase (FT) et géranylgéranyl transférase-1 (GGT) avec des IC50 de 250 nM et 520 nM pour FT et GGT, respectivement. Le mésylate de FGTI-2734 peut empêcher la localisation membranaire de KRAS, résolvant ainsi le problème de résistance À KRAS et contrecarrant les tumeurs pancréatiques dérivées de patients KRAS mutants.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2702297-24-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
FGTI-2734 mesylate is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitor with IC50s of 250 nM and 520 nM for FT and GGT, respectively. FGTI-2734 mesylate can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors[1].
[1]. Kazi A, et al. Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors. Clin Cancer Res. 2019 Jun 21.
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *